enVVeno Medical Corporation is a late clinical-stage medical device company. The Company is focused on the advancement of bioprosthetic (tissue-based) solutions to improve the standard of care for the treatment of venous disease. The Company is developing surgical and non-surgical replacement venous valves for patients suffering from severe chronic venous insufficiency (CVI) of the deep venous system of the leg. The Company’s lead product is the VenoValve, which is a surgical replacement venous valve that is being evaluated in a U.S. pivotal study. The VenoValve is implanted into the femoral vein of the patient in an open surgical procedure via a 5-to-6-inch incision in the upper thigh. The Company is also developing a second product called enVVe, which is a non-surgical, transcatheter-based replacement venous valve. Both the VenoValve and enVVe are designed to act as one-way valves, to help assist in propelling blood up the veins of the leg, and back to the heart and lungs.
企業コードNVNO
会社名enVVeno Medical Corp
上場日May 31, 2018
最高経営責任者「CEO」Berman (Robert A)
従業員数37
証券種類Ordinary Share
決算期末May 31
本社所在地70 Doppler
都市IRVINE
証券取引所NASDAQ OMX - NASDAQ BASIC
国United States of America
郵便番号92618
電話番号19492612900
ウェブサイトhttps://envveno.com/
企業コードNVNO
上場日May 31, 2018
最高経営責任者「CEO」Berman (Robert A)
過去5年間の配当金総支払額は
0.00
米ドルである。

データなし